Get the Daily Brief
Latest Biotech News
Significant Biopharma Financing and Strategic Partnerships Propel Oncology Pipelines
The biotech sector sustains robust funding activity with major financing rounds and strategic licenses advancing oncology drug development. Congruence Therapeutics secured $32 million for protein...
Groundbreaking Microbial and Viral Host Factor Discoveries Inform Drug Targets
New studies have expanded understanding of host-pathogen interactions critical to infectious disease therapeutics. A genome-wide siRNA screen identified key human proteins essential for SARS-CoV-2...
Breakthroughs in Neurodegenerative Disease Diagnostics and Therapeutics
Progress in neurodegenerative diseases continues with novel diagnostic and therapeutic strategies. Octave Bioscience’s proteomic MSDA test gains funding to establish itself as a multiple sclerosis...
Novel Biomaterials and Bioengineering Propel Regenerative Medicine and Cancer Research
Recent material science and bioengineering breakthroughs hold promise for biomedical applications. Innovations include 3D printing devices capable of producing bone grafts intraoperatively, a...
Next-Gen ADCs Dominate NSCLC and Breast Cancer Trials
Recent clinical trials exhibit a breakthrough in antibody-drug conjugates (ADCs) for oncological care, particularly for non-small cell lung cancer (NSCLC) and HER2-positive breast cancer. The...
FDA Advances Transparency: Real-Time Release of Complete Response Letters
The U.S. Food and Drug Administration (FDA) has taken decisive steps to enhance regulatory transparency by initiating real-time public release of complete response letters (CRLs) following their...
Spaceflight Accelerates Aging in Human Hematopoietic Stem Cells
Pioneering research from the University of California San Diego’s Sanford Stem Cell Institute demonstrates that spaceflight expedites aging processes in human hematopoietic stem and progenitor...
Novartis and Argo Biopharma Expand Cardiovascular RNA Therapeutics Collaboration
Novartis and China-based Argo Biopharma have deepened their alliance with a licensing and option agreement valued at up to $5.2 billion targeting RNA interference therapeutics for cardiovascular...
Breakthrough Allogeneic CAR T Therapy Administered in Multiple Sclerosis
The University of Nebraska's Fred & Pamela Buffett Cancer Center has pioneered the treatment of multiple sclerosis (MS) with an allogeneic CD19-directed CAR T-cell therapy, azercabtagene...
Charm Therapeutics Raises $80M to Advance Next-Gen Menin Inhibitors for Leukemia
London-based Charm Therapeutics secured $80 million in a Series B financing round, led by New Enterprise Associates and DR One, to propel clinical development of its next-generation menin...
Gilead Sciences Advances Biomanufacturing with New Facility Groundbreaking
Biopharmaceutical giant Gilead Sciences has commenced construction of a 180,000-square-foot Pharmaceutical Development and Manufacturing Technical Development Center at its California...
Bioinformatics Innovation: Velsera Drives Scalable AI Solutions for Precision Medicine
Velsera, formed by the merger of Seven Bridges, PierianDx, and UgenTec, has emerged as a global platform provider integrating multimodal data harmonization, clinical genomics interpretation, and...
New Insights on Skin Gene Therapy and Acne Vaccine Development
Recent advances in dermatological therapeutics highlight pivotal progress in gene therapy and vaccine development. The gene therapy beremagene geperpavec (B-VEC) has demonstrated substantial...
SARS-CoV-2 Host Dependency Factors Identified for Broad Therapeutic Targeting
Scripps Research scientists employed comprehensive siRNA screening to delineate human proteins essential for SARS-CoV-2 replication, identifying 59 critical host factors operative at early and...
Revolution in EGFR-Mutated NSCLC Treatments: Breakthrough ADC and Osimertinib Combo
A novel bispecific antibody-drug conjugate (ADC) named iza-bren (BL-B01D1) has demonstrated remarkable efficacy when combined with osimertinib, a third-generation EGFR tyrosine kinase inhibitor,...
FDA Transparency: Real-Time Release of Complete Response Letters and Inspection Changes
The U.S. Food and Drug Administration is implementing a new transparency initiative to release complete response letters (CRLs) shortly after sponsors receive them. Building on July's...
Novartis Strengthens RNA Therapeutics with $160M License Deal for Cardiovascular Candidates
Novartis has expanded its RNA-based therapeutic portfolio via a licensing and option agreement valued at up to $5.2 billion with Argo Biopharma, focusing on small interfering RNA (siRNA)...
BioNTech and Duality Biologics Advance Breast Cancer Therapy with ADC Phase 3 Victory
BioNTech and Duality Biologics reported success in a Phase 3 interim analysis for their HER2-targeting antibody-drug conjugate trastuzumab pamirtecan, demonstrating superior progression-free...
Pioneering Allogeneic CAR T Therapy Shows Promise in Progressive Multiple Sclerosis
The University of Nebraska conducted a landmark clinical trial administering allogeneic CD19-directed CAR T-cell therapy (azercabtagene zapreleucel) to a patient with progressive multiple...
ChatGPT and AI in Medical Diagnosis: Opportunities and Challenges Revealed
Recent investigations into the capabilities of ChatGPT and advanced AI algorithms have demonstrated their potential to assist in medical triage and diagnostic uncertainty recognition. While...